Evaluation of Pro-re-Nata (PRN) and treat and extend Bevacizumab treatment protocols in Sorsby Fundus Dystrophy
Evaluation of Pro-re-Nata (PRN) and treat and extend Bevacizumab treatment protocols in Sorsby Fundus Dystrophy
Purpose:
To describe long-term outcomes with intravitreal Bevacizumab for choroidal neovascularization secondary to Sorsby fundus dystrophy.
Materials/methods:
Observational case series.
Results:
Two sisters of the same family formally diagnosed with Sorsby fundus dystrophy were followed-up for 12 years. The elder sister (S1) presented with significant decline in vision due to choroidal neovascularization in her right eye (OD). She developed choroidal neovascularization 3 years later in her left eye (OS). She was treated with Bevacizumab intravitreal injections on a on a pro-re-nata (PRN) until April 2015, when a treat-and-extend (T&E) approach was adopted. Best corrected visual acuities at the time of switch to T&E were 1.09 OD and 0.85 LogMar OS. Best corrected visual acuities at the last follow-up were LogMar 1.1 OD and 0.82 OS. Her younger sister (S2) presented with best corrected visual acuities of LogMar 0.1 OD and 0.0 OS. She developed choroidal neovascularization 5 years later in both eyes. OS developed choroidal neovascularization 18 months after her right eye. She received Bevacizumab on a pro re nata basis until April 2015 when a switch to a T&E was performed. Best corrected visual acuity in the left eye at the switch to T&E was 0.34 LogMar. At the last follow-up, best corrected visual acuities were LogMar 1.2 OD and 0.29 OS.
Conclusion:
Bevacizumab is an effective therapy for choroidal neovascularization secondary to Sorsby fundus dystrophy. A T&E protocol appears more effective compared to pro re nata protocol in minimizing recurrence of choroidal neovascularization with potential secondary scar formation or atrophy.
Best corrected visual acuity, choroidal neovascular membrane, OCT-angiography, Sorsby fundus dystrophy, tissue
Tsokolas, Georgios
13a8eec3-1eb7-4e76-8f04-e8e0a6d78f55
Almuhtaseb, Hussein
27fcdbb3-4784-483d-823c-c6dae6151578
Lotery, Andrew
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514
Tsokolas, Georgios
13a8eec3-1eb7-4e76-8f04-e8e0a6d78f55
Almuhtaseb, Hussein
27fcdbb3-4784-483d-823c-c6dae6151578
Lotery, Andrew
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514
Tsokolas, Georgios, Almuhtaseb, Hussein and Lotery, Andrew
(2018)
Evaluation of Pro-re-Nata (PRN) and treat and extend Bevacizumab treatment protocols in Sorsby Fundus Dystrophy.
European Journal of Ophthalmology.
(doi:10.1177/1120672118811568).
Abstract
Purpose:
To describe long-term outcomes with intravitreal Bevacizumab for choroidal neovascularization secondary to Sorsby fundus dystrophy.
Materials/methods:
Observational case series.
Results:
Two sisters of the same family formally diagnosed with Sorsby fundus dystrophy were followed-up for 12 years. The elder sister (S1) presented with significant decline in vision due to choroidal neovascularization in her right eye (OD). She developed choroidal neovascularization 3 years later in her left eye (OS). She was treated with Bevacizumab intravitreal injections on a on a pro-re-nata (PRN) until April 2015, when a treat-and-extend (T&E) approach was adopted. Best corrected visual acuities at the time of switch to T&E were 1.09 OD and 0.85 LogMar OS. Best corrected visual acuities at the last follow-up were LogMar 1.1 OD and 0.82 OS. Her younger sister (S2) presented with best corrected visual acuities of LogMar 0.1 OD and 0.0 OS. She developed choroidal neovascularization 5 years later in both eyes. OS developed choroidal neovascularization 18 months after her right eye. She received Bevacizumab on a pro re nata basis until April 2015 when a switch to a T&E was performed. Best corrected visual acuity in the left eye at the switch to T&E was 0.34 LogMar. At the last follow-up, best corrected visual acuities were LogMar 1.2 OD and 0.29 OS.
Conclusion:
Bevacizumab is an effective therapy for choroidal neovascularization secondary to Sorsby fundus dystrophy. A T&E protocol appears more effective compared to pro re nata protocol in minimizing recurrence of choroidal neovascularization with potential secondary scar formation or atrophy.
Text
Sorsby Paper Accepted Manuscript-Date of Acceptance 17-10-2018
- Accepted Manuscript
Text
Sorsby_Paper_Accepted_Manuscript_Date_of_Acceptance_17_10_2018
- Accepted Manuscript
Restricted to Repository staff only
Request a copy
Text
Evaluation of Pro-re-Nata(PRN) and teat and Extend Bevacizumab treatment protocols in Sorsby Fundus Distrophy
- Version of Record
Restricted to Repository staff only
Request a copy
More information
Accepted/In Press date: 17 October 2018
e-pub ahead of print date: 13 November 2018
Keywords:
Best corrected visual acuity, choroidal neovascular membrane, OCT-angiography, Sorsby fundus dystrophy, tissue
Identifiers
Local EPrints ID: 426162
URI: http://eprints.soton.ac.uk/id/eprint/426162
ISSN: 1120-6721
PURE UUID: 712a78d5-eb1d-4e7d-9bea-348fb4238cc6
Catalogue record
Date deposited: 15 Nov 2018 17:30
Last modified: 16 Mar 2024 03:32
Export record
Altmetrics
Contributors
Author:
Georgios Tsokolas
Author:
Hussein Almuhtaseb
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
